Page last updated: 2024-11-04

harmaline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Harmaline: A beta-carboline alkaloid isolated from seeds of PEGANUM. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

harmaline : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7 and has been reduced across the 3,4 bond. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3564
CHEMBL ID340807
CHEBI ID28172
CHEBI ID95328
SCHEMBL ID199260
SCHEMBL ID3862598
MeSH IDM0009804

Synonyms (140)

Synonym
BIDD:ER0444
3,4-dihydro-7-methoxy-1-methyl-9-pyrid(3,4-b)indole
harmalol methyl ether
1-methyl-7-methoxy-3,4-dihydro-beta-carboline
o-methylharmalol
3h-pyrido(3,4-b)indole, 4,9-dihydro-7-methoxy-1-methyl-
einecs 206-152-6
4,9-dihydro-7-methoxy-1-methyl-3h-pyrido(3,4-b)indole
3,4-dihydro-7-methoxy-1-methyl-9-pyrido(3,4-b)indole
nsc 407285
brn 0207310
LS-14204
MLS001148231
7-methoxy-1-methyl-4,9-dihydro-3h-beta-carboline
7-methoxy-1-methyl-4,9-dihydro-3h-pyrido[3,4-b]indole
7-methoxy-1-methyl-2,9-dihydro-1h-beta-carboline
bdbm50029799
BRD-K91317041-001-03-8
BRD-K91317041-310-03-3
3h-pyrido[3,4-b]indole, 4,9-dihydro-7-methoxy-1-methyl-
KBIO1_000950
DIVK1C_000950
smr000058221
MLS000028746 ,
SDCCGMLS-0066716.P001
SPECTRUM_000301
IDI1_000950
NCGC00017221-01
tnp00101 ,
BPBIO1_000572
SPECTRUM5_001452
ACON1_000019
BSPBIO_000520
MEGXP0_001874
BSPBIO_002539
nsc-407285
1-methyl-7-methoxy-3,4-dihydro-.beta.-carboline
3,4-dihydroharmine
harmidine
harmine, dihydro-
3,4-b]indole
wln: t b656 dm hm chj f1 ko1
armalin
3h-pyrido[3, 4,9-dihydro-7-methoxy-1-methyl-
dihydroharmine
nsc407285
304-21-2
harmaline
C06536
PRESTWICK3_000610
NCGC00094867-04
NCGC00094867-02
NCGC00094867-03
NCGC00094867-01
KBIOGR_001367
KBIOSS_000781
KBIO2_005917
KBIO2_003349
KBIO2_000781
KBIO3_001759
NINDS_000950
PRESTWICK1_000610
SPECTRUM3_000720
PRESTWICK0_000610
SPBIO_002739
SPECTRUM4_000824
SPBIO_000362
SPECTRUM2_000411
SPECTRUM1500864
PRESTWICK2_000610
OPREA1_112644
NCGC00094867-06
NCGC00094867-05
7-methoxy-1-methyl-4,9-dihydro-3h-b-carboline
H-1100
H-1102
3,4-dihydro-7-methoxy-1-methyl-beta-carboline
3,4-dihydro-7-methoxy-1-methyl-9h-pyrido[3,4-b]indole
H1237
CHEMBL340807 ,
chebi:28172 ,
1-methyl-7-methoxy-3,4-dihydro- beta-carboline
HMS502P12
harmalin
HMS1921K22
7-methoxy-1-methyl-3,4-dihydro-2h-pyrido[3,4-b]indole
hsdb 7645
cn58i4toet ,
unii-cn58i4toet
A820367
HMS2233L23
CCG-38677
NCGC00017221-02
NCGC00017221-04
NCGC00017221-03
NCGC00017221-07
NCGC00017221-06
NCGC00017221-05
7-methoxy-1-methyl-3,4-dihydrobeta-carboline
FT-0626855
AKOS015904564
harmaline [hsdb]
7-methoxy-1-methyl-4,9-dihydro-3h-pyrido(3,4-b)indole
harmaline [mart.]
harmaline [mi]
S4776
4,9-dihydro-7-methoxy-1-methyl-3h-pyrido[3,4-b]indole
HMS3371G17
SCHEMBL199260
SCHEMBL3862598
KS-5325
A1-00783
7-methoxy-1-methyl-4,9-dihydro-3h-?-carboline
3,4-dihydro-7-methoxy-1-methyl-9h-pyrid[3,4-b]indole
7-methoxy-1-methyl-4,9-dihydro-3h-beta-carboline #
AC-34436
OPERA_ID_665
mfcd00004955
DTXSID8041038
AKOS026750619
SR-01000721899-4
SR-01000721899-5
sr-01000721899
CHEBI:95328
HY-107828
CS-0030704
3, 4-dihydroharmine
dihydro-harmine
1-methyl-7-methoxy-3,4-dihydro-beta -carboline
3,4-dihydro-7-methoxy-1-methyl-9-pyrid[3,4-b]indole
1-methyl-7-methoxy-3, 4-dihydro-beta -carboline
3,4-dihydro-7-methoxy-1-methyl-b-carboline
DB13875
Q135270
7-methoxy-1-methyl-3,4-dihydro-2h-beta-carboline
HMS3885P22
STL570451
nsc789037
nsc-789037
PD056221

Research Excerpts

Overview

Harmaline is a beta-carboline alkaloid that can be extracted from Peganum harmala. It is a tremorigenic drug known to induce enhanced and rhythmic firing of the inferior olive.

ExcerptReferenceRelevance
"Harmaline is a naturally occurring β-carboline alkaloid that is isolated from Peganum harmala. "( Harmaline isolated from Peganum harmala suppresses growth of esophageal squamous cell carcinoma through targeting mTOR.
Hwang, J; Kim, DJ; Laster, KV; Liu, K; Pang, M; Shi, X; Xie, X; Zhang, Y, 2021
)
3.51
"Harmaline is a β-carboline alkaloid that can be extracted from the seeds of Peganum harmala. "( Harmaline exerts potentially anti-cancer effects on U-87 human malignant glioblastoma cells in vitro.
Afshari, AR; Bahrami, A; Ferns, GA; Garousi, S; Mottahedi, M; Pouyamanesh, G; Shahini, A; Shariat Razavi, SA; Vahedi, MM, 2023
)
3.8
"Harmaline is a beta-carboline alkaloid showing neuroprotective and neurotoxic properties. "( Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.
Jiang, XL; Shen, HW; Wu, C; Yu, AM, 2009
)
2.09
"Harmaline (HA) is a beta-carboline commonly known to provoke motor alterations through activation of cells in the inferior olive. "( Effects of harmaline on anxiety-related behavior in mice.
Chapillon, P; Hilber, P, 2005
)
2.16
"Harmaline is a tremorigenic drug known to induce enhanced and rhythmic firing of the inferior olive."( MAPK activation in cerebellar basket cell terminals after harmaline treatment.
Andjus, P; Buffo, A; Carulli, D; Milasin, J; Strata, P, 2005
)
1.29

Effects

Harmaline has been shown to exhibit a potent cytotoxic effect against tumor cells. Harmaline also has been found by other investigators to competitively inhibit L-lysine uptake by the Na(+)-independent system asc1.

ExcerptReferenceRelevance
"Harmaline has been also known as the main nociceptive agent extracted from the Peganum harmala plant."( Basolateral amygdala cannabinoid CB1 receptors mediate the antinociceptive activity of harmaline in adolescent male mice.
Alijanpour, S; Ebrahimi-Ghiri, M; Ghasemzadeh, Z; Zarrindast, MR, 2022
)
1.67
"Harmaline has been shown to exhibit a potent cytotoxic effect against tumor cells."( Harmaline exerts potentially anti-cancer effects on U-87 human malignant glioblastoma cells in vitro.
Afshari, AR; Bahrami, A; Ferns, GA; Garousi, S; Mottahedi, M; Pouyamanesh, G; Shahini, A; Shariat Razavi, SA; Vahedi, MM, 2023
)
3.07
"Harmaline has been extensively studied in last decade and known to exert multiple pharmacological effects including antileishmanial, antimicrobial, antiplatelet, antiplasmodial, antitumoral, hypothermic and vasorelaxant activity."( Recent pharmacological developments in β-carboline alkaloid "harmaline".
Iqbal, Z; Khan, FA; Maalik, A; Malik, I, 2013
)
1.35
"Harmaline also has been found by other investigators to competitively inhibit L-lysine uptake by the Na(+)-independent system asc1 in horse erythrocytes, whereas it noncompetitively inhibits alanine uptake by the same system."( Inhibition of transport system b0,+ in blastocysts by inorganic and organic cations yields insight into the structure of its amino acid receptor site.
Campione, AL; Gorman, JM; Van Winkle, LJ, 1990
)
1
"Harmaline has been used to produce long-term activation of the climbing fibre projection to the cerebellar cortex and the effects on parallel fibre transmission to Purkinje cells were studied electrophysiologically. "( Modification of parallel fibre-Purkinje cell transmission by long-term activation of climbing fibres.
Rawson, JA; Rees, S; Wertheimer, S, 1988
)
1.72

Actions

Harmaline is known to produce tremors and retard acquisition of the rabbit's nictitating membrane response. Harmaline can inhibit L-phenylalanine influx at a concentration at which it does not affect intracellular ion concentrations.

ExcerptReferenceRelevance
"Harmaline also could increase glutamate levels in vermis and treatment with riluzole restored glutamate levels."( Effects of riluzole on harmaline induced tremor and ataxia in rats: biochemical, histological and behavioral studies.
Abrari, K; Elahdadi Salmani, M; Goudarzi, A; Goudarzi, I; Lashkarbolouki, T; Rahimi Shourmasti, F, 2012
)
1.41
"Harmaline is known to produce tremors and retard acquisition of the rabbit's nictitating membrane response. "( Harmaline-induced tremor and impairment of learning are both blocked by dizocilpine in the rabbit.
Du, W; Harvey, JA, 1997
)
3.18
"Harmaline can inhibit L-phenylalanine influx at a concentration at which it does not affect intracellular ion concentrations."( Differential effects of harmaline and ouabain on intestinal sodium, phenylalanine and beta-methyl-glucoside transport.
Buclon, M; Robinson, JW; Sepúlveda, FV, 1976
)
1.28
"Harmaline did not inhibit additively the TEA uptake in the presence of amiloride or choline."( Effect of harmaline on organic ion transport in rabbit renal cortical slices.
Kim, YK; Lee, SH; Park, YS,
)
1.26
"1. Harmaline was found to inhibit the Na+-Ca2+ exchange mechanism present in cardiac sarcolemmal vesicles. "( Inhibition of Na+-Ca2+ exchange mechanism in cardiac sarcolemmal vesicles by harmaline.
Reeves, JP; Suleiman, MS, 1987
)
1.12
"Harmaline was found to inhibit human erythrocyte system ASC noncompetitively with respect to L-alanine concentration, but approximated competitive inhibition with respect to Na+ concentration (apparent Ki = 2.0 and 0.9 mM, respectively)."( Topographical similarities between harmaline inhibition sites on Na+-dependent amino acid transport system ASC in human erythrocytes and Na+-independent system asc in horse erythrocytes.
Fincham, DA; Mason, DK; Young, JD, 1988
)
1.27
"Harmaline was found to increase cell excitability by hyperpolarizing the neurones and shifting the inactivation curve for the somatic Ca2+ spike to a more positive membrane potential level."( Oscillatory properties of guinea-pig inferior olivary neurones and their pharmacological modulation: an in vitro study.
Llinás, R; Yarom, Y, 1986
)
0.99

Treatment

Harmaline treatment had no later effects on the climbing fiber EPSC kinetics and I/V relation in Purkinje cells (P15-36) In harmaline-pretreated rats, tryptophan also increased the central 5-HT levels (80.5%-95.5% increase) in the hypothermic state.

ExcerptReferenceRelevance
"Harmaline treatment was also associated with an upregulation of the cell cycle-related genes, p21 and p53, and pro-apoptotic Bax, as well as the induction of ROS."( Harmaline exerts potentially anti-cancer effects on U-87 human malignant glioblastoma cells in vitro.
Afshari, AR; Bahrami, A; Ferns, GA; Garousi, S; Mottahedi, M; Pouyamanesh, G; Shahini, A; Shariat Razavi, SA; Vahedi, MM, 2023
)
3.07
"Harmaline treatment resulted in characteristic tremor that lasted for more than 2 hours and decreased the locomotor activity of rats. "( Low-dose acute vanillin is beneficial against harmaline-induced tremors in rats.
Abdulrahman, AA; Arshaduddin, M; Faisal, K; Meshref, AA, 2017
)
2.16
"Harmaline treatment lead to cytoplasm vacuolization, mitochondrial disruption, spherocrystals with concentric layers, irregular nucleus and floating nuclei in cytoplasm."( Apolipophorin III and transmission electron microscopy as toxicity indicators for harmaline and tea saponin in Spodoptera exigua (Noctuidae: Lepidoptera).
Gong, L; Hu, M; Luo, J; Rizwan-ul-Haq, M, 2011
)
1.32
"Harmaline treatment had no later effects on the climbing fiber EPSC kinetics and I/V relation in Purkinje cells (P15-36)."( A change in the pattern of activity affects the developmental regression of the Purkinje cell polyinnervation by climbing fibers in the rat cerebellum.
Andjus, PR; Carulli, D; Cesa, R; Strata, P; Zhu, L, 2003
)
1.04
"In harmaline-pretreated rats, tryptophan also increased the central 5-HT levels (80.5%-95.5% increase) in the hypothermic state, and the effect peaked at about 1 hr after tryptophan administration."( Central serotonin level-dependent changes in body temperature following administration of tryptophan to pargyline- and harmaline-pretreated rats.
Abdel-Fattah, AF; Adel-Khalek Gammaz, H; Matsumoto, K; Mohamed, MF; Murakami, Y; Watanabe, H, 1997
)
1.02
"Pre-treatment with harmaline or harmine (3, 10 or 30 microM) shifted the phenylephrine-induced dose response curves to the right and the maximum response was attenuated indicating that the antagonist effect of both alkaloids on alpha1-adrenorecepteors was non-competitive."( Vasorelaxant effects of harmine and harmaline extracted from Peganum harmala L. seeds in isolated rat aorta.
Berrougui, H; Ettaib, A; Herrera, MD; Hmamouchi, M; Khalil, A; Marhuenda, E; Martín-Cordero, C, 2006
)
0.93
"Treatment with harmaline also increased cyclic 3',5'-guanosine monophosphate (cGMP) in the cerebellum, presumably through activation of the climbing fiber pathway from the inferior olive to the cerebellar cortex."( Tolerance to the tremorogenic effects of harmaline: evidence for altered olivo-cerebellar function.
Beales, M; Lorden, JF; Lutes, J; Oltmans, GA, 1988
)
0.88

Toxicity

ExcerptReferenceRelevance
" Accordingly, intracellular hydrogen ion concentrations were measured in cultured hippocampal neurons with the fluorescent dye BCECF during and after toxic exposures."( Changes in intracellular pH associated with glutamate excitotoxicity.
Dubinsky, JM; Hartley, Z, 1993
)
0.29
" That a lesion of the inferior olive almost completely prevents the neurotoxicity demonstrates that ibogaine is not directly toxic to Purkinje cells, but that the toxicity is indirect and dependent on integrity of the olivocerebellar projection."( The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity.
Molliver, ME; O'Hearn, E, 1997
)
0.3
" All betaCs and MPP(+) showed general cytotoxicity in parental HEK-293 cells after 72 h with half-maximal toxic concentrations (TC(50) values) in the upper micromolar range."( Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake.
Beach, JW; Collins, MA; Gearhart, DA; Hwang, YI; Neafsey, EJ; Schwarz, J; Storch, A, 2004
)
0.32
" Their use is frequently associated with dose-limiting adverse effects."( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.
Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I,
)
0.13
" For detecting side effect liability (ataxia, sedation, impairment of voluntary motor functions), (1) the rota-rod test, (2) measurement of spontaneous motility, (3) the weight-lifting test and (4) the thiopental sleep test were used."( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.
Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I,
)
0.13
"Therapeutic indices calculated from the results of these in vivo experiments for the clinically used muscle relaxants are in agreement with their adverse effect profiles in humans."( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.
Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I,
)
0.13

Pharmacokinetics

This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK.

ExcerptReferenceRelevance
" In addition, the pharmacokinetic and pharmacodynamic drug-drug interactions between harmaline and 5-MeO-DMT, potential involvement of CYP2D6 pharmacogenetics, and risks of 5-MeO-DMT intoxication are discussed."( Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
Jiang, XL; Shen, HW; Winter, JC; Yu, AM, 2010
)
0.58
" This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine."( Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.
Jiang, XL; Mager, DE; Shen, HW; Yu, AM, 2013
)
0.9

Compound-Compound Interactions

Harmaline alone and in combination with chlorhexidine digluconate (CHG) against clinical isolates of Staphylococcus aureus (S.A.) The study was an evaluation of proliferation, cytotoxicity and differentiation of harmine and harmaline on HL60 cells.

ExcerptReferenceRelevance
" The present study was an evaluation of proliferation, cytotoxicity and differentiation of harmine and harmaline on HL60 cells, alone or in combination with ATRA and G-CSF."( A study on the antitumoral and differentiation effects of peganum harmala derivatives in combination with ATRA on leukaemic cells.
Arjmand, A; Oody, A; Zaker, F, 2007
)
0.55
" In addition, the pharmacokinetic and pharmacodynamic drug-drug interactions between harmaline and 5-MeO-DMT, potential involvement of CYP2D6 pharmacogenetics, and risks of 5-MeO-DMT intoxication are discussed."( Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
Jiang, XL; Shen, HW; Winter, JC; Yu, AM, 2010
)
0.58
"  To investigate the antimicrobial efficacy of an alkaloid, harmaline alone and in combination with chlorhexidine digluconate (CHG) against clinical isolates of Staphylococcus aureus (S."( Antimicrobial efficacy of the alkaloid harmaline alone and in combination with chlorhexidine digluconate against clinical isolates of Staphylococcus aureus grown in planktonic and biofilm cultures.
Chen, Z; Guo, N; Li, Y; Liu, L; Shen, F; Sun, S; Wang, W; Wang, X; Wu, X; Xing, M; Yu, L; Zhang, K, 2012
)
0.89

Bioavailability

ExcerptReferenceRelevance
") did not affect cGMP responses, suggesting poor bioavailability in brain."( Indole-2-carboxylates, novel antagonists of the N-methyl-D-aspartate (NMDA)-associated glycine recognition sites: in vivo characterization.
Cler, JA; Cordi, AA; Dappen, MS; Emmett, MR; Gray, NM; Iyengar, S; Mick, SJ; Monahan, JB; Rao, TS; Wood, PL, 1993
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Repeated dosing for 14 days did not enhance MAO-A inhibition."( SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
Bizière, K; Kan, JP; Mouget-Goniot, C; Steinberg, R; Worms, P, 1987
)
0.27
" Pargyline and tranylcypromine shifted the dose-response curves for tyramine and beta-phenylethylamine, but not serotonin, to the left, indicating inhibition of type B MAO."( Some cardiovascular effects of monoamine oxidase inhibitors in unanaesthetized rats.
Huston, V; Marwood, JF; Wall, KT,
)
0.13
"0 mg/kg) in an acute dosing regime."( At low doses, harmaline increases forelimb tremor in the rat.
Fowler, SC; Stanford, JA, 1998
)
0.66
" Mitochondrial swelling occurs in cerebellar stellate and basket cells within 30 minutes of dosing and persists for more than 12 hours without leading to cell death."( The effects of the tremorgenic mycotoxin penitrem A on the rat cerebellum.
Cavanagh, JB; Holton, JL; Mantle, PG; Naik, JT; Nolan, CC; Ray, DE, 1998
)
0.3
" Dosing continued for 4 consecutive days."( Concurrent quantification of tremor and depression of locomotor activity induced in rats by harmaline and physostigmine.
Fowler, SC; Wang, G, 2001
)
0.53
" A gene dosage effect (deficits in the +/- mice) on these two variables became apparent in the older mice."( Motor and associative deficits in D2 dopamine receptor knockout mice.
Chen, R; Fowler, SC; Vorontsova, E; Zarcone, TJ,
)
0.13
", fast and slow metabolizers of harmine-in 14 experienced male members of the União do Vegetal (UDV) who received a standardized dosage of hoasca."( Fast and slow metabolizers of Hoasca.
Callaway, JC, 2005
)
0.33
" The in vivo assay was done on 60 experimentally infected pigeons dosed with metronidazole at 50 mg/kg body weight (BW) or alkaloids at 25 mg/kg BW."( Antitrichomonal activity of Peganum harmala alkaloid extract against trichomoniasis in pigeon (Columba livia domestica).
Moghadamnia, AA; Tabari, MA; Youssefi, MR, 2017
)
0.46
" However, large differences in tremor intensity and intermittency were observed across individual subjects under similar dosing levels."( Considerations Using Harmaline for a Primate Model of Tremor.
Bello, EM; Blumenfeld, M; Dao, J; Johnson, MD; Krieg, JDS; Wilmerding, LK, 2021
)
0.94
"5 ng/mouse) enhanced the ineffective dose-response of harmaline on pain threshold in the tail-flick or hot plate tests, respectively."( Basolateral amygdala cannabinoid CB1 receptors mediate the antinociceptive activity of harmaline in adolescent male mice.
Alijanpour, S; Ebrahimi-Ghiri, M; Ghasemzadeh, Z; Zarrindast, MR, 2022
)
1.19
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
oneirogenAny substance that produces or enhances dream-like states of consciousness.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
harmala alkaloidAny member of a class of naturally occurring alkaloids based on a 1-methyl-9H-beta-carboline skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
beta-carboline biosynthesis09

Protein Targets (64)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency25.11890.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency6.30960.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.31620.044717.8581100.0000AID485294
Chain A, HADH2 proteinHomo sapiens (human)Potency32.18410.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency32.18410.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.30850.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency33.24180.125919.1169125.8920AID2549; AID504841
Chain A, Ferritin light chainEquus caballus (horse)Potency35.48135.623417.292931.6228AID485281
Chain A, CruzipainTrypanosoma cruziPotency10.00000.002014.677939.8107AID1476
ATAD5 protein, partialHomo sapiens (human)Potency9.20000.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency18.49390.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency16.36080.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency30.86790.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency31.62280.001318.074339.8107AID926; AID938
alpha-galactosidaseHomo sapiens (human)Potency35.48134.466818.391635.4813AID2107
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency89.12510.035520.977089.1251AID504332
serine-protein kinase ATM isoform aHomo sapiens (human)Potency35.48130.707925.111941.2351AID485349
Bloom syndrome protein isoform 1Homo sapiens (human)Potency35.48130.540617.639296.1227AID2528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency3.98110.00207.533739.8107AID891
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency22.38720.036619.637650.1187AID1466; AID2242
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency32.90900.001815.663839.8107AID894
huntingtin isoform 2Homo sapiens (human)Potency15.84890.000618.41981,122.0200AID1688
importin subunit beta-1 isoform 1Homo sapiens (human)Potency1.29955.804836.130665.1308AID540253
DNA polymerase betaHomo sapiens (human)Potency35.48130.022421.010289.1251AID485314
snurportin-1Homo sapiens (human)Potency1.29955.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency1.29955.804816.996225.9290AID540253
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency12.58930.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency3.26430.004611.374133.4983AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency22.38720.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency19.95260.031610.279239.8107AID884; AID885
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency28.18380.00419.962528.1838AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency22.38720.251215.843239.8107AID504327
caspase-1 isoform alpha precursorHomo sapiens (human)Potency12.58930.000311.448431.6228AID900
lethal factor (plasmid)Bacillus anthracis str. A2012Potency25.11890.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency7.07950.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency22.38723.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency22.38723.548118.039535.4813AID1466
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Caspase-7Homo sapiens (human)Potency11.29473.981118.585631.6228AID889
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency10.00001.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseElectrophorus electricus (electric eel)IC50 (µMol)4.90000.00000.94539.9400AID656680
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)IC50 (µMol)150.00000.00040.764912.5000AID126695
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)IC50 (µMol)0.01200.00071.979812.5000AID125713
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)0.03290.00002.37899.7700AID1706696
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)23.70000.00000.933210.0000AID656684
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)100.00000.00001.89149.5700AID1706697
5-hydroxytryptamine receptor 5AHomo sapiens (human)Ki10.00000.00080.94335.1600AID6500
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
STE24Saccharomyces cerevisiae (brewer's yeast)AC502.76601.95006.687011.8600AID488815
dual specificity tyrosine-phosphorylation-regulated kinase 1ARattus norvegicus (Norway rat)AC501.23600.00564.693226.6940AID588345
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (53)

Processvia Protein(s)Taxonomy
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 5AHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 5AHomo sapiens (human)
hippocampus development5-hydroxytryptamine receptor 5AHomo sapiens (human)
response to estradiol5-hydroxytryptamine receptor 5AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 5AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 5AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 5AHomo sapiens (human)
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 5AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 5AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 5AHomo sapiens (human)
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 5AHomo sapiens (human)
perikaryon5-hydroxytryptamine receptor 5AHomo sapiens (human)
postsynaptic specialization membrane5-hydroxytryptamine receptor 5AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 5AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 5AHomo sapiens (human)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (185)

Assay IDTitleYearJournalArticle
AID435727Percentage JNK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435374Percentage PLK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1181720Antimicrobial activity against promastigote stage of Leishmania donovani after 72 hrs by Alamar Blue assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis, antileishmanial and antitrypanosomal activities of N-substituted tetrahydro-β-carbolines.
AID126695In vitro inhibitory activity against rat brain Monoamine oxidase B1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives.
AID435747Percentage PRAK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435814Percentage PIM3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1478470Antiproliferative activity against human PC3 cells by MTT assay2017Journal of natural products, 02-24, Volume: 80, Issue:2
Structurally Diverse Alkaloids from the Seeds of Peganum harmala.
AID435493Percentage PKD1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID436076Percentage DYRK1A activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1181721Antimicrobial activity against axenic amastigote stage of Leishmania donovani after 72 hrs by Alamar Blue assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis, antileishmanial and antitrypanosomal activities of N-substituted tetrahydro-β-carbolines.
AID435723Percentage GSK3-beta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435363Percentage MELK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID55536Percentage inhibition against cyclin dependent kinase 5 (CDK 5) at a concentration of 50 uM2002Bioorganic & medicinal chemistry letters, Apr-08, Volume: 12, Issue:7
Beta-carbolines as specific inhibitors of cyclin-dependent kinases.
AID435233Percentage HIPK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435756Percentage Src activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID333916Genotoxicity in CHO cells assessed as chromosomal aberrations at 10 ppm after 90 mins in dark
AID435704Percentage Aurora B activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID333906Genotoxicity in CHO cells assessed as chromosomal aberrations at 2.5 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins
AID343393Antileishmanial activity against Leishmania infantum promastigotes2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.
AID435820Percentage PKCalpha activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435541Percentage PKA activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435315Percentage MARK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID436037Percentage MAPKAPK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1706698Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B2021European journal of medicinal chemistry, Jan-01, Volume: 209Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity.
AID436036Percentage Lck activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435681Percentage MAPKAPK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435370Percentage p38beta MAPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435454Percentage CaMKKalpha activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1706697Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate preincubated for 15 mins followed by substrate addition and measured over 20 mins by horse-radish peroxidase/Amplex Red coupled2021European journal of medicinal chemistry, Jan-01, Volume: 209Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity.
AID435350Percentage ERK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID333919Genotoxicity in CHO cells assessed as chromosomal aberrations at 0.31 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins
AID333915Genotoxicity in CHO cells assessed as chromosomal aberrations at 10 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins
AID435883Percentage SGK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID436083Percentage ERK8 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID6500Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Binding of tetrahydrocarboline derivatives at human 5-HT5A receptors.
AID1478471Antiproliferative activity against human SGC7901 cells by MTT assay2017Journal of natural products, 02-24, Volume: 80, Issue:2
Structurally Diverse Alkaloids from the Seeds of Peganum harmala.
AID435734Percentage NEK6 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435256Percentage p38-gamma MAPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID473138Antiplatelet aggregation activity against collagen-induced platelet2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
A class of 3S-2-aminoacyltetrahydro-beta-carboline-3-carboxylic acids: their facile synthesis, inhibition for platelet activation, and high in vivo anti-thrombotic potency.
AID125713In vitro inhibitory activity against rat brain Monoamine oxidase A1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives.
AID435317Percentage PIM1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1706696Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate preincubated for 15 mins followed by substrate addition and measured over 20 mins by horse-radish peroxidase/Amplex Red coupled2021European journal of medicinal chemistry, Jan-01, Volume: 209Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity.
AID343394Antileishmanial activity against Leishmania mexicana amazonensis promastigotes2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.
AID333920Genotoxicity in CHO cells assessed as chromosomal aberrations at 0.15 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins
AID435418Percentage PAK5 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID436072Percentage CK1delta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1713264Antileishmanial activity against late log phase promastigote stage of Leishmania infantum MHOM/FR/78/LEM75 assessed as inhibition of parasite growth incubated for 48 hrs by hemocytometer counting method2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and anti-leishmanial evaluation of 1-phenyl-2,3,4,9-tetrahydro-1H-β-carboline derivatives against Leishmania infantum.
AID435854Percentage IKK-beta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435995Percentage SRPK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID333917Genotoxicity in CHO cells assessed as mitotic inhibition at 1.25 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins
AID435223Percentage CSK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435731Percentage MNK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID436071Percentage CHK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435713Percentage CHK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID333904Genotoxicity in CHO cells assessed as mitotic inhibition at 5 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins
AID435865Percentage MKK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435300Percentage PAK6 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID436086Percentage HIPK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435842Percentage Aurora C activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID656681Inhibition of electric eel AChE using acetylcholine iodide as substrate at 10'-4 M measured every 5 sec for 2 mins by Ellman's method2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Prospective acetylcholinesterase inhibitory activity of indole and its analogs.
AID435867Percentage NEK2a activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435417Percentage PAK4 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435613Percentage MNK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435250Percentage MSK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID55535Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM2002Bioorganic & medicinal chemistry letters, Apr-08, Volume: 12, Issue:7
Beta-carbolines as specific inhibitors of cyclin-dependent kinases.
AID435979Percentage MST2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1478469Antiproliferative activity against human HL60 cells by tryphan blue assay2017Journal of natural products, 02-24, Volume: 80, Issue:2
Structurally Diverse Alkaloids from the Seeds of Peganum harmala.
AID435228Percentage ERK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435375Percentage RSK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID625776Antiplatelet activity in rabbit platelets assessed as inhibition of collagen-induced platelet aggregation2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
A class of novel N-(1-methyl-β-carboline-3-carbonyl)-N'-(aminoacid-acyl)-hydrazines: aromatization leaded design, synthesis, in vitro anti-platelet aggregation/in vivo anti-thrombotic evaluation and 3D QSAR analysis.
AID435718Percentage EF2K activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID343385Inhibition of Trypanosoma cruzi recombinant trypanothione reductase at 85 uM2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.
AID435881Percentage ROCK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435215Percentage AMPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435669Percentage PDK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435706Percentage BRSK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435847Percentage DYRK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID656684Inhibition of human AChE by Ellman's method2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Prospective acetylcholinesterase inhibitory activity of indole and its analogs.
AID234093Selectivity for the B form was estimated by the IC50(MAO A)/IC50(MAO B) ratio.1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives.
AID1181717Antimicrobial activity against promastigote stage of Leishmania infantum2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis, antileishmanial and antitrypanosomal activities of N-substituted tetrahydro-β-carbolines.
AID435728Percentage JNK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID333918Genotoxicity in CHO cells assessed as mitotic inhibition at 0.62 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins
AID1882176Antifungal activity against Candida albicans incubated for 72 hrs2022European journal of medicinal chemistry, Feb-05, Volume: 229Natural and synthetic β-carboline as a privileged antifungal scaffolds.
AID435987Percentage PRK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435738Percentage p38delta MAPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435427Percentage PKBalpha activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435539Percentage PHK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435962Percentage CDK2-cyclinA activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435123Percentage NEK7 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435339Percentage CaMKKbeta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID656685Inhibition of human AChE at 10'-4 M by Ellman's method2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Prospective acetylcholinesterase inhibitory activity of indole and its analogs.
AID435501Percentage SmMLCK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435260Percentage RSK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435621Percentage p38alpha MAPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435176Percentage PIM2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435373Percentage PKCzeta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID656680Inhibition of electric eel AChE using acetylcholine iodide as substrate measured every 5 sec for 2 mins by Ellman's method2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Prospective acetylcholinesterase inhibitory activity of indole and its analogs.
AID435461Percentage CK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435238Percentage JNK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1181716Antimicrobial activity against amastigote stage of Leishmania infantum2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis, antileishmanial and antitrypanosomal activities of N-substituted tetrahydro-β-carbolines.
AID435819Percentage PKBbeta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435225Percentage DYRK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435338Percentage CaMK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435378Percentage S6K1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347391qHTS for activators of Nrf2/ARE signaling pathway screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347402qHTS for inhibitors of Rabies Virus screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID134737610-beta competent E. coli microbial cell viability qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347393qHTS for inhibitors of ER calcium dysfunction: SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347394Vero-766 cells viability qHTS against the NCATS CANVASS Library: Counterscreen for Zika virus inhibition assay2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347387Cytotoxicity qHTS for assessment of Hepg2 cells membrane integrity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347346HPAF-II Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347350SW1088 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347366KB-3-1 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347378qHTS for H2AX Agonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347380qHTS for Antimalaria activity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347369MCF7 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347360HPAF-II 18hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347367qHTS for ATAD5 Agonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347352COV-362 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347357HEK293 18hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347401Redox Reaction Profiling qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347388qHTS for Activators of p53 Stress Response Pathway screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347348OV-SAHO Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347368G06 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347372qHTS for Constitutive Androstane Receptor (CAR) Antagonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347363Firefly luciferase counterscreen qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347345OV-KATE Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347374qHTS for Hypoxia signaling pathway (HIF-1) antagonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347358HPAF-II 12hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347373qHTS for Constitutive Androstane Receptor (CAR) Agonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347347UWB1.289 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347365SDT Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347396qHTS for inhibitors of Wild type Zika virus screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347361HEK293 12hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347351U-118MG Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347359HEK293 24hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347349Panc-1005 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347379qHTS for Inflammasome Signaling Inhibitors: IL-1-beta AlphaLISA screen against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347355HEK-293 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347353A2780 Cisplatin Sensitive Ovarian Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347375qHTS for Hypoxia signaling pathway (HIF-1) agonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347354UWB1.289-WTBRCA1 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347381Inflammasome Signaling qHTS Counterscreen: IL-1-beta AlphaLISA counterscreen against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347362Diaphorse counterscreen qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347377DH5-alpha competent E. coli microbial cell viability qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347390Secretion counterscreen for inhibitors of the SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347356HPAF-II 24hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347389qHTS assay for small molecule disruptors of mitochondrial membrane potential screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347364KB-8-5-11 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347400Viability qHTS for inhibitors of the SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347370qHTS for ATAD5 Antagonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347371J3T Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347392qHTS for activators of dead-cell proteases activity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (606)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990276 (45.54)18.7374
1990's105 (17.33)18.2507
2000's83 (13.70)29.6817
2010's101 (16.67)24.3611
2020's41 (6.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.12 (24.57)
Research Supply Index6.46 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index76.15 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.32%)5.53%
Reviews25 (3.95%)6.00%
Case Studies2 (0.32%)4.05%
Observational0 (0.00%)0.25%
Other604 (95.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]